How does ruxolitinib tablets (JAKAVI) work?

Ruxolitinib tablets (JAKAVI, Ruxolitinib) is a selective Janus kinase (JAK) inhibitor that mainly targets JAK1 and JAK2. JAK is a type of tyrosine kinase that plays an important role in the signaling process of cytokines and growth factors, especially in hematopoiesis and immune regulation. By inhibiting JAK1 and JAK2, ruxolitinib tablets can regulate signaling and affect cell proliferation, inflammatory response and immune function.

Ruxolitinib tablets are mainly used to treat diseases such as primary myelofibrosis (PMF), polycythemia vera (PV), and steroid-refractory acute graft-versus-host disease (aGVHD). In these diseases, the JAK-STAT signaling pathway is abnormally activated, leading to hematopoietic system disorders, spleen enlargement, and elevated levels of inflammatory factors. By blocking this signaling pathway, ruxolitinib tablets can reduce spleen enlargement, relieve symptoms, and reduce the release of inflammatory mediators, thereby improving the patient's quality of life.

In patients with myelofibrosis, ruxolitinib tablets can reduce the proliferation of abnormal hematopoietic stem cells and reduce the levels of pro-inflammatory cytokines by inhibiting the JAK2 signaling pathway. This not only helps reduce the size of the spleen, but also improves symptoms such as fatigue, night sweats, and weight loss, while extending the patient's survival. For patients with polycythemia vera, ruxolitinib tablets can inhibit the production of abnormal red blood cells, reduce the risk of thrombosis, control the number of blood cells, and reduce dependence on bloodletting treatment.

In addition, in acute graft-versus-host disease (aGVHD), the JAK inhibition of ruxolitinib tablets can regulate the immune system and reduce the abnormal activation of T cells, thereby reducing immune-mediated tissue damage. Research shows that ruxolitinib tablets can improve the symptoms of hormone-refractory aGVHD patients, improve treatment response rate, and increase survival rate. Therefore, ruxolitinib tablets have become one of the important targeted treatments for these blood and immune-related diseases.

xa0

Reference materials:https://www.jakavi.com/